BIO Medical Applications Of Alabama Inc is a medicare approved dialysis facility center in Decatur, Alabama and it has 20 dialysis stations. It is located in Morgan county at 2834 Spring Avenue Sw, Decatur, AL, 35603. You can reach out to the office of BIO Medical Applications Of Alabama Inc at (256) 885-1740. This dialysis clinic is managed and/or owned by Fresenius Medical Care. BIO Medical Applications Of Alabama Inc has the following ownership type - Profit. It was first certified by medicare in February, 2017. The medicare id for this facility is 012692 and it accepts patients under medicare ESRD program.
| Name | BIO Medical Applications Of Alabama Inc |
|---|---|
| Location | 2834 Spring Avenue Sw, Decatur, Alabama |
| No. of Dialysis Stations | 20 |
| Medicare ID | 012692 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 2834 Spring Avenue Sw, Decatur, Alabama, 35603 | |
| (256) 885-1740 | |
| Not Available |
News Archive
The inaugural issue of BioResearch Open Access, a new bimonthly peer-reviewed open access journal, was released today by Mary Ann Liebert, Inc., publishers. The Journal provides a new rapid-publication forum for a broad range of scientific topics including but not limited to molecular and cellular biology, tissue engineering and biomaterials, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience.
Cubist Pharmaceuticals, Inc. and Adolor Corporation today announced the results of Cubist's initial tender offer to purchase all of the outstanding shares of common stock of Adolor.
Collierville now has a new choice for treating Orthopedic problems, sports injuries and a variety of conditions that cause pain. Results Physiotherapy has opened a new physical therapy clinic in Collierville, and it is the fifth location in the greater Memphis area.
Maxygen, Inc., a biotechnology company, today announced that its Board of Directors has approved an increase to the company's current stock repurchase program from $10.0 million to $20.0 million. The repurchase program expires on December 31, 2011.
The Centers for Disease Control and Prevention (CDC) issued a letter detailing a case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an immunocompromised patient who did not respond well to monoclonal antibody treatment. The resistance to treatment stemmed from an escape mutation on the spike protein known as Q4923R.
› Verified 6 days ago
| NPI Number | 1760839922 |
| Organization Name | Fresenius Medical Care Decatur |
| Doing Business As | Bio-medical Applications Of Alabama, Inc. |
| Address | 2834 Spring Ave Sw Decatur, Alabama, 35603 |
| Phone Number | (256) 306-4735 |
News Archive
The inaugural issue of BioResearch Open Access, a new bimonthly peer-reviewed open access journal, was released today by Mary Ann Liebert, Inc., publishers. The Journal provides a new rapid-publication forum for a broad range of scientific topics including but not limited to molecular and cellular biology, tissue engineering and biomaterials, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience.
Cubist Pharmaceuticals, Inc. and Adolor Corporation today announced the results of Cubist's initial tender offer to purchase all of the outstanding shares of common stock of Adolor.
Collierville now has a new choice for treating Orthopedic problems, sports injuries and a variety of conditions that cause pain. Results Physiotherapy has opened a new physical therapy clinic in Collierville, and it is the fifth location in the greater Memphis area.
Maxygen, Inc., a biotechnology company, today announced that its Board of Directors has approved an increase to the company's current stock repurchase program from $10.0 million to $20.0 million. The repurchase program expires on December 31, 2011.
The Centers for Disease Control and Prevention (CDC) issued a letter detailing a case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an immunocompromised patient who did not respond well to monoclonal antibody treatment. The resistance to treatment stemmed from an escape mutation on the spike protein known as Q4923R.
› Verified 6 days ago
| Dialysis patients with Hemoglobin data | 11 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 27 |
News Archive
The inaugural issue of BioResearch Open Access, a new bimonthly peer-reviewed open access journal, was released today by Mary Ann Liebert, Inc., publishers. The Journal provides a new rapid-publication forum for a broad range of scientific topics including but not limited to molecular and cellular biology, tissue engineering and biomaterials, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience.
Cubist Pharmaceuticals, Inc. and Adolor Corporation today announced the results of Cubist's initial tender offer to purchase all of the outstanding shares of common stock of Adolor.
Collierville now has a new choice for treating Orthopedic problems, sports injuries and a variety of conditions that cause pain. Results Physiotherapy has opened a new physical therapy clinic in Collierville, and it is the fifth location in the greater Memphis area.
Maxygen, Inc., a biotechnology company, today announced that its Board of Directors has approved an increase to the company's current stock repurchase program from $10.0 million to $20.0 million. The repurchase program expires on December 31, 2011.
The Centers for Disease Control and Prevention (CDC) issued a letter detailing a case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an immunocompromised patient who did not respond well to monoclonal antibody treatment. The resistance to treatment stemmed from an escape mutation on the spike protein known as Q4923R.
› Verified 6 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 28 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 128 |
| Percentage of adult patients getting regular hemodialysis at the center | 98 |
News Archive
The inaugural issue of BioResearch Open Access, a new bimonthly peer-reviewed open access journal, was released today by Mary Ann Liebert, Inc., publishers. The Journal provides a new rapid-publication forum for a broad range of scientific topics including but not limited to molecular and cellular biology, tissue engineering and biomaterials, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience.
Cubist Pharmaceuticals, Inc. and Adolor Corporation today announced the results of Cubist's initial tender offer to purchase all of the outstanding shares of common stock of Adolor.
Collierville now has a new choice for treating Orthopedic problems, sports injuries and a variety of conditions that cause pain. Results Physiotherapy has opened a new physical therapy clinic in Collierville, and it is the fifth location in the greater Memphis area.
Maxygen, Inc., a biotechnology company, today announced that its Board of Directors has approved an increase to the company's current stock repurchase program from $10.0 million to $20.0 million. The repurchase program expires on December 31, 2011.
The Centers for Disease Control and Prevention (CDC) issued a letter detailing a case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an immunocompromised patient who did not respond well to monoclonal antibody treatment. The resistance to treatment stemmed from an escape mutation on the spike protein known as Q4923R.
› Verified 6 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at BIO Medical Applications Of Alabama Inc with elevated calcium levels.
| Patients with hypercalcemia | 28 |
| Hypercalcemia patient months | 128 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 30 |
| Patients with Serumphosphor less than 3.5 mg/dL | 1 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 19 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 26 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 37 |
| Patients with Serumphosphor greater than 7 mg/dL | 16 |
News Archive
The inaugural issue of BioResearch Open Access, a new bimonthly peer-reviewed open access journal, was released today by Mary Ann Liebert, Inc., publishers. The Journal provides a new rapid-publication forum for a broad range of scientific topics including but not limited to molecular and cellular biology, tissue engineering and biomaterials, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience.
Cubist Pharmaceuticals, Inc. and Adolor Corporation today announced the results of Cubist's initial tender offer to purchase all of the outstanding shares of common stock of Adolor.
Collierville now has a new choice for treating Orthopedic problems, sports injuries and a variety of conditions that cause pain. Results Physiotherapy has opened a new physical therapy clinic in Collierville, and it is the fifth location in the greater Memphis area.
Maxygen, Inc., a biotechnology company, today announced that its Board of Directors has approved an increase to the company's current stock repurchase program from $10.0 million to $20.0 million. The repurchase program expires on December 31, 2011.
The Centers for Disease Control and Prevention (CDC) issued a letter detailing a case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an immunocompromised patient who did not respond well to monoclonal antibody treatment. The resistance to treatment stemmed from an escape mutation on the spike protein known as Q4923R.
› Verified 6 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 30 |
| Patient months included in arterial venous fistula and catheter summaries | 137 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 77 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 9 |
News Archive
The inaugural issue of BioResearch Open Access, a new bimonthly peer-reviewed open access journal, was released today by Mary Ann Liebert, Inc., publishers. The Journal provides a new rapid-publication forum for a broad range of scientific topics including but not limited to molecular and cellular biology, tissue engineering and biomaterials, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience.
Cubist Pharmaceuticals, Inc. and Adolor Corporation today announced the results of Cubist's initial tender offer to purchase all of the outstanding shares of common stock of Adolor.
Collierville now has a new choice for treating Orthopedic problems, sports injuries and a variety of conditions that cause pain. Results Physiotherapy has opened a new physical therapy clinic in Collierville, and it is the fifth location in the greater Memphis area.
Maxygen, Inc., a biotechnology company, today announced that its Board of Directors has approved an increase to the company's current stock repurchase program from $10.0 million to $20.0 million. The repurchase program expires on December 31, 2011.
The Centers for Disease Control and Prevention (CDC) issued a letter detailing a case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an immunocompromised patient who did not respond well to monoclonal antibody treatment. The resistance to treatment stemmed from an escape mutation on the spike protein known as Q4923R.
› Verified 6 days ago
Home Dialysis Of North Alabama Location: 1216 Sommerville Road, Se, Decatur, Alabama, 35601 Phone: (256) 340-0012 |
BIO Medical Applications Of Alabama Inc Location: 2834 Spring Avenue Sw, Decatur, Alabama, 35603 Phone: (256) 885-1740 |
News Archive
The inaugural issue of BioResearch Open Access, a new bimonthly peer-reviewed open access journal, was released today by Mary Ann Liebert, Inc., publishers. The Journal provides a new rapid-publication forum for a broad range of scientific topics including but not limited to molecular and cellular biology, tissue engineering and biomaterials, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience.
Cubist Pharmaceuticals, Inc. and Adolor Corporation today announced the results of Cubist's initial tender offer to purchase all of the outstanding shares of common stock of Adolor.
Collierville now has a new choice for treating Orthopedic problems, sports injuries and a variety of conditions that cause pain. Results Physiotherapy has opened a new physical therapy clinic in Collierville, and it is the fifth location in the greater Memphis area.
Maxygen, Inc., a biotechnology company, today announced that its Board of Directors has approved an increase to the company's current stock repurchase program from $10.0 million to $20.0 million. The repurchase program expires on December 31, 2011.
The Centers for Disease Control and Prevention (CDC) issued a letter detailing a case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an immunocompromised patient who did not respond well to monoclonal antibody treatment. The resistance to treatment stemmed from an escape mutation on the spike protein known as Q4923R.
› Verified 6 days ago